Search hospitals > New Jersey > Newark
Newark Beth Israel Medical Center
Claim this profileNewark, New Jersey 07112
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Leukemia
Conducts research for Lymphoblastic Leukemia-Lymphoma
Conducts research for Tumors
388 reported clinical trials
21 medical researchers
Summary
Newark Beth Israel Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Breast Cancer, Cancer, Leukemia, Lymphoblastic Leukemia-Lymphoma, Tumors and other specialties. Newark Beth Israel Medical Center is involved with conducting 388 clinical trials across 531 conditions. There are 21 research doctors associated with this hospital, such as Teena Bhatla, Howard S. Hochster, Missak Haigentz, MD, and Patrick M. Boland.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Teena BhatlaNewark Beth Israel Medical Center4 years of reported clinical research
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
24 reported clinical trials
61 drugs studied
Howard S. HochsterRutgers Cancer Institute of New Jersey4 years of reported clinical research
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
37 drugs studied
Missak Haigentz, MDRutgers Cancer Institute of New Jersey3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
14 reported clinical trials
23 drugs studied
Patrick M. BolandRutgers Cancer Institute of New Jersey4 years of reported clinical research
Studies Colon Cancer
Studies Colorectal Cancer
9 reported clinical trials
18 drugs studied
Clinical Trials running at Newark Beth Israel Medical Center
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Diffuse Large B-Cell Lymphoma
Cancer
Gallbladder Cancer
Lymphoma
Colon Cancer
Ovarian Tumors
Acute Leukemia
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Newark Beth Israel Medical Center?
Newark Beth Israel Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Breast Cancer, Cancer, Leukemia, Lymphoblastic Leukemia-Lymphoma, Tumors and other specialties. Newark Beth Israel Medical Center is involved with conducting 388 clinical trials across 531 conditions. There are 21 research doctors associated with this hospital, such as Teena Bhatla, Howard S. Hochster, Missak Haigentz, MD, and Patrick M. Boland.
Where is Newark Beth Israel Medical Center located?
The Newark Beth Israel Medical Center is located at 201 Lyons Ave, Newark, NJ 07112.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Newark Beth Israel Medical Center, contact the billing department at 973-926-6517. For insurance inquiries, refer to the hospital's phone directory for a dedicated insurance line. Uninsured and underinsured patients meeting specific income and asset criteria may be eligible for the New Jersey Hospital Care Payment Assistance Program (Charity Care).
What insurance does Newark Beth Israel Medical Center accept?
Newark Beth Israel Medical Center, part of RWJBarnabas Health, accepts a wide range of insurance plans including but not limited to Blue Cross/Blue Shield, Commonwealth Care, Harvard Pilgrim Health Care, Neighborhood Health Plan, Mass Health/Medicaid, Medicare, Tufts, and most commercial insurances. They also provide services to patients without insurance. For a detailed list of accepted insurance plans, refer to the RWJBarnabas Health Contracted Health Insurers and Networks list. Note: It's crucial to verify with your physician if they participate in the same insurance plans as the hospital.
What awards or recognition has Newark Beth Israel Medical Center received?
Newark Beth Israel Medical Center is celebrated as one of the World's Best Hospitals by Newsweek for five consecutive years, making it one of seven New Jersey hospitals to achieve this distinction. It has earned the American Heart Association's Get With The Guidelines Gold Award for Heart Failure and Resuscitation. Additionally, it has received the American College of Cardiology's Performance Achievement Award for Cardiac Care.